A 32-year-old woman with systemic lupus erythematosus (SLE) on mycophenolate mofetil (MMF) 2 g/day presents with severe diarrhea, abdominal cramping, and weight loss over 2 weeks. Laboratory investigations show hemoglobin 9.2 g/dL, WBC 2.1 × 10⁹/L, and platelets 85 × 10⁹/L. Stool culture and C. difficile toxin are negative. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient presents with a classic presentation of **mycophenolate mofetil (MMF) toxicity**: diarrhea, cytopenias (anemia, leukopenia, thrombocytopenia), and constitutional symptoms in the absence of infectious causes. ## Mechanism of MMF-Induced Toxicity MMF is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH) in lymphocytes. However, it can cause dose-dependent gastrointestinal and hematologic toxicity, particularly in patients with: - Renal impairment (reduced clearance of active metabolite) - Concurrent medications affecting metabolism - Genetic polymorphisms in UGT1A8/1A9 (reduced glucuronidation) **Key Point:** MMF-induced cytopenias and GI toxicity are NOT infectious in origin and require immediate drug discontinuation, not symptomatic management. ## Management Algorithm ```mermaid flowchart TD A[Patient on MMF with diarrhea + cytopenias]:::outcome --> B{Infectious cause ruled out?}:::decision B -->|Yes| C[MMF toxicity suspected]:::outcome C --> D{Severity of cytopenias?}:::decision D -->|Mild| E[Reduce MMF dose]:::action D -->|Moderate-Severe| F[Discontinue MMF immediately]:::action F --> G[Switch to alternative agent<br/>Azathioprine or Tacrolimus]:::action E --> H[Monitor CBC + symptoms]:::action G --> I[Reassess in 2-4 weeks]:::action ``` ## Why Discontinuation is Necessary **High-Yield:** The cytopenias (Hb 9.2, WBC 2.1, platelets 85) indicate **moderate-to-severe bone marrow suppression**. Continuing or merely reducing the dose risks: - Severe anemia requiring transfusion - Opportunistic infections (WBC < 2.5 × 10⁹/L) - Hemorrhagic complications (platelets < 100 × 10⁹/L) **Clinical Pearl:** Azathioprine is the preferred alternative in SLE because it: - Has a different mechanism (purine antagonist) — no cross-toxicity - Is well-established in lupus nephritis - Allows time for bone marrow recovery (typically 1–2 weeks) ## Why Other Options Are Incorrect | Option | Why Wrong | |--------|----------| | Continue + loperamide | Masking symptoms while organ damage (marrow suppression) continues; antiperistaltic agents worsen toxicity | | Reduce to 1 g/day | Insufficient in moderate-severe cytopenias; dose reduction alone does not prevent further marrow injury | | Colonoscopy | Infectious and drug-induced causes already ruled out; colonoscopy delays critical intervention | **Warning:** Do NOT confuse MMF toxicity with infectious colitis — the absence of C. difficile and normal stool culture, combined with cytopenias, points to direct drug toxicity.